In last trading session, Emergent Biosolutions Inc (NYSE:EBS) saw 1.19 million shares changing hands with its beta currently measuring 1.59. Company’s recent per share price level of $9.14 trading at -$0.02 or -0.22% at ring of the bell on the day assigns it a market valuation of $493.74M. That closing price of EBS’s stock is at a discount of -65.21% from its 52-week high price of $15.10 and is indicating a premium of 84.46% from its 52-week low price of $1.42. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.19 million shares which gives us an average trading volume of 2.88 million if we extend that period to 3-months.
For Emergent Biosolutions Inc (EBS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.33. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Emergent Biosolutions Inc (NYSE:EBS) trade information
Upright in the red during last session for losing -0.22%, in the last five days EBS remained trading in the green while hitting it’s week-highest on Wednesday, 10/16/24 when the stock touched $9.14 price level, adding 2.77% to its value on the day. Emergent Biosolutions Inc’s shares saw a change of 280.83% in year-to-date performance and have moved 8.17% in past 5-day. Emergent Biosolutions Inc (NYSE:EBS) showed a performance of 32.46% in past 30-days. Number of shares sold short was 8.23 million shares which calculate 3.12 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 51.5 to the stock, which implies a rise of 82.25% to its current value. Analysts have been projecting 38 as a low price target for the stock while placing it at a high target of 65. It follows that stock’s current price would drop -315.75% in reaching the projected high whereas dropping to the targeted low would mean a loss of -315.75% for stock’s current value.
Emergent Biosolutions Inc (EBS) estimates and forecasts
Statistics highlight that Emergent Biosolutions Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 391.40% of value to its shares in past 6 months, showing an annual growth rate of 79.13% while that of industry is 17.50. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Emergent Biosolutions Inc (NYSE:EBS)’s Major holders
Insiders are in possession of 2.13% of company’s total shares while institution are holding 57.57 percent of that, with stock having share float percentage of 58.82%. Investors also watch the number of corporate investors in a company very closely, which is 57.57% institutions for Emergent Biosolutions Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at EBS for having 3.84 million shares of worth $26.18 million. And as of 2024-06-30, it was holding 7.3551 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 3.67 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.0234 of outstanding shares, having a total worth of $25.0 million.
